BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol. 2010;66:837-844. [PMID: 20041325 DOI: 10.1007/s00280-009-1226-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Rusolo F, Pucci B, Colonna G, Capone F, Guerriero E, Milone MR, Nazzaro M, Volpe MG, Di Bernardo G, Castello G, Costantini S. Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines. Molecules. 2013;18:2549-2562. [PMID: 23442931 DOI: 10.3390/molecules18032549] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
2 Duff B, Reddy Thangella V, Creaven BS, Walsh M, Egan DA. Anti-cancer activity and mutagenic potential of novel copper(II) quinolinone Schiff base complexes in hepatocarcinoma cells. European Journal of Pharmacology 2012;689:45-55. [DOI: 10.1016/j.ejphar.2012.06.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
3 Ghione S, Mabrouk N, Paul C, Bettaieb A, Plenchette S. Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. Biochem Pharmacol 2020;176:113855. [PMID: 32061562 DOI: 10.1016/j.bcp.2020.113855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
5 Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2010;10:1635-1646. [PMID: 20942634 DOI: 10.1586/era.10.146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
7 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Zhou J, Li W, Guo J, Li G, Chen F, Zhou J. Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma. Tumour Biol 2016;37:3561-9. [PMID: 26456956 DOI: 10.1007/s13277-015-4109-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
9 Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A, Pontisso P. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. J Control Release 2017;268:184-97. [PMID: 29051062 DOI: 10.1016/j.jconrel.2017.10.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
10 Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 2014;15:474. [PMID: 25472660 DOI: 10.1186/1745-6215-15-474] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
11 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, Abbruzzese A, Caraglia M, Palmieri G. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012;3:e259. [PMID: 22258409 DOI: 10.1038/cddis.2011.136] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
13 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
14 Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Lett. 2016;371:205-213. [PMID: 26679051 DOI: 10.1016/j.canlet.2015.11.039] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
15 Kalinina O, Marchio A, Urbanskii AI, Tarkova AB, Rebbani K, Granov DA, Dejean A, Generalov MI, Pineau P. Somatic changes in primary liver cancer in Russia: A pilot study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2013;755:90-9. [DOI: 10.1016/j.mrgentox.2013.06.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, Hosseinzadeh F, Iranikhah A, Shirian S. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int 2018;18:133. [PMID: 30214375 DOI: 10.1186/s12935-018-0624-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 29.6] [Reference Citation Analysis]
18 Gnoni A, Licchetta A, Memeo R, Argentiero A, Solimando AG, Longo V, Delcuratolo S, Brunetti O. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. Medicina (Kaunas) 2019;55:E754. [PMID: 31766556 DOI: 10.3390/medicina55120754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
19 Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, Sperlongano R, Iodice P, Russo P, Del Prete S. Sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Oncology. 2013;84:265-272. [PMID: 23428832 DOI: 10.1159/000345558] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
20 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
21 Zhu W, Zhang Q, Liu M, Yan M, Chu X, Li Y. Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer. Cancer Cell Int 2021;21:81. [PMID: 33516217 DOI: 10.1186/s12935-021-01779-1] [Reference Citation Analysis]
22 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352 [PMID: 23898367 DOI: 10.4254/wjh.v5.i7.345] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 13.4] [Reference Citation Analysis]
24 Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012;69:773-780. [PMID: 22033636 DOI: 10.1007/s00280-011-1753-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
25 Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Eur J Cancer 2017;86:106-14. [PMID: 28985579 DOI: 10.1016/j.ejca.2017.09.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
26 Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57:1122-1129. [PMID: 22451120 DOI: 10.1007/s10620-012-2136-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
27 Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol 2016; 22(27): 6114-6126 [PMID: 27468204 DOI: 10.3748/wjg.v22.i27.6114] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
28 Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer. 2014;21:R485-R493. [PMID: 25336571 DOI: 10.1530/erc-14-0389] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
29 Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, Wang Z, Qiu SJ, Fan J, Zhou J. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2012;11:458-466. [PMID: 23060390 DOI: 10.1016/s1499-3872(12)60209-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
30 Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol 2017;15:e2000487. [PMID: 28158308 DOI: 10.1371/journal.pbio.2000487] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
31 Rafiullah, Ali A, Mohiuddin H, Zahid U, Abushahin L. Innovations in the Management of Hepatocellular Carcinoma. American Journal of Therapeutics 2018;25:e362-8. [DOI: 10.1097/mjt.0000000000000713] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
33 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
34 Chiu CM, Huang SY, Chang SF, Liao KF, Chiu SC. Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells. Onco Targets Ther 2018;11:1777-85. [PMID: 29636623 DOI: 10.2147/OTT.S161534] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
35 Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530. [PMID: 25460347 DOI: 10.1371/journal.pone.0112530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
36 Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol. 2014;91:1-8. [PMID: 24457121 DOI: 10.1016/j.critrevonc.2013.12.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
37 Tuo L, Xiang J, Pan X, Gao Q, Zhang G, Yang Y, Liang L, Xia J, Wang K, Tang N. PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway. Front Oncol 2018;8:611. [PMID: 30619751 DOI: 10.3389/fonc.2018.00611] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
38 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
39 Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. Onco Targets Ther 2015;8:3193-202. [PMID: 26586953 DOI: 10.2147/OTT.S94246] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Tian Y, Liu Y, Qu J, Li K, Qin D, Huang A, Tang H. HBV regulated RhoC expression in HepG2.2.15 cells by enhancing its promoter activity: HBV regulated RhoC expression in HepG2.2.15 cells. J Basic Microbiol 2013;53:461-8. [DOI: 10.1002/jobm.201200063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
42 Zhou S, Ye W, Duan X, Zhang M, Wang J. The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. Dig Dis Sci 2013;58:1615-26. [PMID: 23314856 DOI: 10.1007/s10620-012-2537-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
43 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin 2017;38:614-22. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 282] [Cited by in F6Publishing: 262] [Article Influence: 56.4] [Reference Citation Analysis]
44 Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. [PMID: 21985599 DOI: 10.1186/1479-5876-9-171] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 13.0] [Reference Citation Analysis]
45 Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:1-8. [PMID: 28847184 DOI: 10.1080/17474124.2017.1373018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
46 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
47 Gentilini D, Scala S, Gaudenzi G, Garagnani P, Capri M, Cescon M, Grazi GL, Bacalini MG, Pisoni S, Dicitore A, Circelli L, Santagata S, Izzo F, Di Blasio AM, Persani L, Franceschi C, Vitale G. Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach. Oncotarget 2017;8:41890-902. [PMID: 28514750 DOI: 10.18632/oncotarget.17462] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
48 Kim H, Park CK, Lee SJ, Rha SY, Park KH, Lim HY. PIK3CA mutations in hepatocellular carcinoma in Korea. Yonsei Med J. 2013;54:883-887. [PMID: 23709421 DOI: 10.3349/ymj.2013.54.4.883] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2:e150. [PMID: 21525937 DOI: 10.1038/cddis.2011.34] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
50 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
51 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
52 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
53 Jiang L, Ping L, Yan H, Yang X, He Q, Xu Z, Luo P. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opin Drug Metab Toxicol 2020;16:823-35. [PMID: 32597258 DOI: 10.1080/17425255.2020.1787986] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 2012;42:523-42. [PMID: 22568457 DOI: 10.1111/j.1872-034X.2012.00981.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
55 Yordanova A, Hose D, Neben K, Witzens-harig M, Gütgemann I, Raab M, Moehler T, Goldschmidt H, Schmidt-wolf IG. Sorafenib in patients with refractory or recurrent multiple myeloma: Sorafenib in myeloma. Hematol Oncol 2013;31:197-200. [DOI: 10.1002/hon.2043] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
56 Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, Tamaki S, Kato T, Yasui Y, Hosokawa T. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:251-258. [PMID: 22116493 DOI: 10.1159/000334454] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]